Gregory Cox is Assistant General Patent Counsel at Eli Lilly and Company. His primary responsibilities include global preparation and prosecution of patents covering various late stage bioproduct clinical candidates. He also manages all IP due diligences for in bound and out bound assets, and provides advise on IP issues related to business development deals. Greg has held several presentations in which he explains Eli Lilly’s policy to not support functional antibody claims. He has also authored an amicus curiae brief for Eli Lilly to support Sanofi’s position in the Amgen vs Sanofi case, where epitope based anti PCSK9 antibody claims are under scrutiny.